Breaking News: FDA Approves Loqtorzi (Toripalimab TPZI) for All Stages of Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) – A Major Milestone for Coherus and Junshi Biosciences
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) LOQTORZI™ (toripalimab-tpzi) Carton LOQTORZI is the first and only FDA-approved treatment for NPC LOQTORZI™ (toripalimab-tpzi) has been making waves in the medical community as the first and only FDA-approved treatment for Nasopharyngeal Carcinoma (NPC). This new drug, indicated in combination with chemotherapy for 1st line…